Federico Rojo
YOU?
Author Swipe
View article: Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2– Highly Proliferative Breast Cancer
Neoadjuvant Abemaciclib plus Letrozole vs. Chemotherapy in patients with HR+/HER2– Highly Proliferative Breast Cancer Open
Purpose: Neoadjuvant chemotherapy is standard for high-risk HR+/HER2–breast cancer (BC). This study evaluates whether 12 months of letrozole plus abemaciclib could be an alternative. Patients and Methods: The phase II, open-label CARABELA …
View article: Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Appendix S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Nonauthor Collaborators
View article: Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Receiver operating characteristics (ROC) curves data of FOXC1 Score (VFOXC1) versus IHC phenotype and PAM50 intrinsic subtype in basal-like/non-basal categories definitions
View article: Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of disease-free survival (DFS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Data from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Purpose:In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non–basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from adj…
View article: Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S3 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Forest plot for the GEICAM_CIBOMA translational study cohort primary endpoint of recurrence-free survival (RFS) on the capecitabine arm versus observation arm for basal-like/non-basal categories variables
View article: Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S8 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of 5-year and 8-year recurrence-free survival (RFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Patient’s distribution by VFOXC1 and Ki67
View article: Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S4 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Inter-assay agreement assessment by Kappa index between basal-like/non-basal categories variables
View article: Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Figure S2 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Survival analyses showing the secondary endpoint of overall survival (OS) for patients randomly assigned to capecitabine or observation in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S9 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Disease-free survival (DFS) events for basal-like/non-basal subpopulations by VFOXC1 in the GEICAM_CIBOMA translational analysis
View article: Supplementary Table S5 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S5 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of distant relapse-free survival (DRFS) for VFOXC1 plus Ki67 IHC subgroups in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S7 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S7 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of overall survival (OS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S6 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Multivariate Cox regression analysis of disease-free survival (DFS) for basal-like/non-basal categories variables in the GEICAM_CIBOMA translational study cohort
View article: Supplementary Table S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
Supplementary Table S1 from FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Patient’s distribution by the standardized FOXC1 IHC test Proportion Score (PS) and Intensity Score (IS
View article: Effects of presurgical <scp>HIIT</scp> in hormone receptor‐positive, <scp>HER</scp> 2‐negative breast cancer cases: Two case reports from the <scp>GEICAM EFiK</scp> study
Effects of presurgical <span>HIIT</span> in hormone receptor‐positive, <span>HER</span> 2‐negative breast cancer cases: Two case reports from the <span>GEICAM EFiK</span> study Open
The purpose of this study was to determine the effects of a high‐intensity interval‐training (HIIT) or stretching‐balance intervention 3 weeks prior to surgery in two hormone receptor‐positive and human‐epidermal growth‐factor receptor 2‐n…
View article: TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak
TIM3+ breast cancer cells license immune evasion during micrometastasis outbreak Open
In metastasis, the dynamics of tumor-immune interactions during micrometastasis remain unclear. Identifying the vulnerabilities of micrometastases before outbreaking into macrometastases can reveal therapeutic opportunities for metastasis.…
View article: FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial
FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial Open
Purpose: In a prespecified GEICAM_CIBOMA trial (NCT00130533) correlative analysis, PAM50 non–basal-like breast cancer (non-BLBC) status distinguished patients with triple-negative breast cancer (TNBC) who are most likely to benefit from ad…
View article: MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer
MET pathway inhibition increases chemo-immunotherapy efficacy in small cell lung cancer Open
The introduction of immunotherapy as a first-line treatment for advanced small cell lung cancer (SCLC) represents significant progress, yet there remains an opportunity to further improve patient outcomes. Hepatocyte growth factor (HGF) re…
View article: <i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis
<i>BRCA1/2</i> and Other Predisposition Genes in High-Risk Hormone Receptor+/Human Epidermal Growth Factor Receptor 2– Breast Cancer Treated With Endocrine Therapy With or Without Palbociclib: A Secondary PENELOPE-B Study Analysis Open
PURPOSE The PENELOPE-B trial (ClinicalTrials.gov identifier: NCT01864746 ) recruited patients with hormone receptor+/human epidermal growth factor receptor 2– early breast cancer without a pathological complete response after taxane-contai…
View article: Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer
Adaptive Proteomic Changes in Protein Metabolism and Mitochondrial Alterations Associated with Resistance to Trastuzumab and Pertuzumab Therapy in HER2-Positive Breast Cancer Open
HER2 (human epidermal growth factor receptor 2) is overexpressed in approximately 15–20% of breast cancers, leading to aggressive tumour growth and poor prognosis. Anti-HER2 therapies, such as trastuzumab and pertuzumab, have significantly…
View article: The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer
The Potential of Single-Transcription Factor Gene Expression by RT-qPCR for Subtyping Small Cell Lung Cancer Open
Complex RNA-seq signatures involving the transcription factors ASCL1, NEUROD1, and POU2F3 classify Small Cell Lung Cancer (SCLC) into four subtypes: SCLC-A, SCLC-N, SCLC-P, and SCLC-I (triple negative or inflamed). Preliminary studies sugg…
View article: Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping
Dynamics of molecular heterogeneity in high-risk luminal breast cancer—From intrinsic to adaptive subtyping Open
We evaluate therapy-induced molecular heterogeneity in longitudinal samples from high-risk, hormone-receptor positive/HER2-negative breast cancer patients with residual tumor after neoadjuvant chemotherapy from the Penelope-B trial (NCT018…
View article: New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era
New therapeutic approaches for EGFR mutated non-small cell lung cancer on osimertinib era Open
This study highlights the prognostic impact of co-mutations, particularly TP53, in EGFRmut NSCLC treated with osimertinib. These findings underscore the need for novel therapeutic approaches and personalized treatment strategies, especiall…